Q: What is Ultomiris used for?

Ultomiris is used to treat the following conditions: Paroxysmal nocturnal hemoglobinuria Atypical hemolytic uremic syndrome Generalized myasthenia gravis

Q: How does Ultomiris work?

The Complement System Ultomiris belongs to a class of medications called complement inhibitors. The complement system is a group of proteins in the blood that form part of the body's natural immune defense. In certain conditions, this system becomes overactive and begins to attack and destroy healthy cells instead of just fighting germs. Targeting the C5 Protein This medication works by binding to a specific protein in the complement system known as C5. By attaching to this protein, Ultomiris prevents it from breaking down and triggering a cascade of immune responses that cause damage. This process helps to: Prevent red blood cell destruction: In conditions like paroxysmal nocturnal hemoglobinuria (PNH), it stops the immune system from breaking apart red blood cells. Protect blood vessels: In atypical hemolytic uremic syndrome (aHUS), it prevents the formation of small blood clots and damage to the lining of blood vessels. Reduce nerve and muscle damage: In generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD), it blocks the immune attacks that lead to muscle weakness and inflammation of the central nervous system. Ultomiris is engineered to remain active in the bloodstream for a long period, providing sustained suppression of the complement system to manage symptoms and prevent disease progression.

Q: What are the active ingredients in Ultomiris?

The active ingredient in Ultomiris is ravulizumab .

Q: What are the side effects of Ultomiris?

Common side effects of Ultomiris may include: Upper respiratory tract infection Diarrhea Headache Others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Ultomiris?

Ultomiris belongs to the complement inhibitor drug class.

Q: Is Ultomiris safe during pregnancy and breastfeeding?

Pregnancy Data regarding the use of Ultomiris in pregnant women is currently insufficient to determine if there is a drug-associated risk of birth defects or miscarriage. However, it is known that human antibodies can cross the placenta, especially during the later stages of pregnancy. If you are pregnant or planning to become pregnant, consult your healthcare provider to discuss the necessity of the treatment and any potential risks to the fetus. Breastfeeding It is unknown if Ultomiris is present in human breast milk or how it might affect a nursing child. Because many drugs are excreted in breast milk and could cause serious adverse reactions, you should discuss with your doctor whether to continue breastfeeding or stop the medication.

Q: What forms and strengths does Ultomiris come in?

Intravenous Infusion Ultomiris is supplied as a concentrated solution in single-dose vials. This form is administered by a healthcare professional as an infusion into a vein (intravenous) after being diluted. Subcutaneous Injection Ultomiris is also available as a solution in a single-dose prefilled cartridge. This form is administered as an injection under the skin (subcutaneous) using a wearable on-body injector.

Q: What is the FDA approval status of Ultomiris?

FDA Approval and Indications Ultomiris was first approved by the U.S. Food and Drug Administration (FDA) in December 2018. It is currently approved for the treatment of the following conditions: Paroxysmal nocturnal hemoglobinuria (PNH): To treat adults and children one month of age and older. Atypical hemolytic uremic syndrome (aHUS): To treat adults and children one month of age and older to inhibit complement-mediated thrombotic microangiopathy. Generalized myasthenia gravis (gMG): To treat adults who are anti-acetylcholine receptor (AChR) antibody-positive. Neuromyelitis optica spectrum disorder (NMOSD): To treat adults who are anti-aquaporin-4 (AQP4) antibody-positive. Boxed Warning Ultomiris carries a boxed warning regarding the risk of serious and life-threatening meningococcal infections. These infections can become fatal if they are not recognized and treated early. Because the medication interferes with the body's immune response, it increases susceptibility to specific types of bacteria. REMS Program Due to the risk of meningococcal infections, Ultomiris is only available through a restricted program called the Ultomiris REMS (Risk Evaluation and Mitigation Strategy). Requirements of this program include: Healthcare providers who prescribe the medication must be specially certified and enrolled in the program. Patients must be vaccinated against meningococcal infection at least two weeks before receiving their first dose, unless the treatment is urgent and cannot be delayed. Patients must be monitored for early signs of infection and receive a Patient Safety Card that they must carry at all times during treatment.

Question 1

What is Ultomiris?

Accepted Answer

Ultomiris is a type of medication known as a complement inhibitor. It is designed to target and bind to the C5 protein, which is a part of the immune system's complement cascade.

By inhibiting this protein, the medication helps prevent the immune system from damaging healthy cells and tissues. This mechanism is used to manage the underlying biological activity of certain chronic diseases.

Question 2

What is Ultomiris used for?

Accepted Answer

Ultomiris is used to treat the following conditions:

Paroxysmal nocturnal hemoglobinuria
Atypical hemolytic uremic syndrome
Generalized myasthenia gravis

Question 3

How does Ultomiris work?

Accepted Answer

The Complement System

Ultomiris belongs to a class of medications called complement inhibitors. The complement system is a group of proteins in the blood that form part of the body's natural immune defense. In certain conditions, this system becomes overactive and begins to attack and destroy healthy cells instead of just fighting germs.

Targeting the C5 Protein

This medication works by binding to a specific protein in the complement system known as C5. By attaching to this protein, Ultomiris prevents it from breaking down and triggering a cascade of immune responses that cause damage. This process helps to:

Prevent red blood cell destruction: In conditions like paroxysmal nocturnal hemoglobinuria (PNH), it stops the immune system from breaking apart red blood cells.
Protect blood vessels: In atypical hemolytic uremic syndrome (aHUS), it prevents the formation of small blood clots and damage to the lining of blood vessels.
Reduce nerve and muscle damage: In generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD), it blocks the immune attacks that lead to muscle weakness and inflammation of the central nervous system.

Ultomiris is engineered to remain active in the bloodstream for a long period, providing sustained suppression of the complement system to manage symptoms and prevent disease progression.

Question 4

What are the active ingredients in Ultomiris?

Accepted Answer

The active ingredient in Ultomiris is ravulizumab.

Question 5

What are the side effects of Ultomiris?

Accepted Answer

Common side effects of Ultomiris may include:

Upper respiratory tract infection
Diarrhea
Headache
Others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Ultomiris?

Accepted Answer

Ultomiris belongs to the complement inhibitor drug class.

Question 7

What is the dosage of Ultomiris and how do I take it?

Accepted Answer

Administration Methods

Ultomiris is administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection. The specific method and schedule depend on the condition being treated and the patient's body weight.

Intravenous Infusion

Intravenous doses are administered by a healthcare professional into a vein. The infusion process typically takes place in a clinical setting and lasts for several hours. Following an initial loading dose, maintenance infusions are generally scheduled every few weeks.

Subcutaneous Injection

Subcutaneous doses are injected under the skin of the abdomen, thigh, or upper arm. This method is typically used for maintenance therapy after an initial intravenous loading dose. Patients or caregivers may be able to perform these injections at home once they have received proper training from a healthcare provider. These injections are usually administered once a week.

Missed Doses

Maintaining a consistent schedule is critical for the effectiveness of the treatment. If a dose is missed, it is important to contact a healthcare provider immediately to determine the next steps. Do not attempt to catch up by taking extra doses without medical guidance.

Question 8

Is Ultomiris safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Data regarding the use of Ultomiris in pregnant women is currently insufficient to determine if there is a drug-associated risk of birth defects or miscarriage. However, it is known that human antibodies can cross the placenta, especially during the later stages of pregnancy.

If you are pregnant or planning to become pregnant, consult your healthcare provider to discuss the necessity of the treatment and any potential risks to the fetus.

Breastfeeding

It is unknown if Ultomiris is present in human breast milk or how it might affect a nursing child. Because many drugs are excreted in breast milk and could cause serious adverse reactions, you should discuss with your doctor whether to continue breastfeeding or stop the medication.

Question 9

What forms and strengths does Ultomiris come in?

Accepted Answer

Intravenous Infusion

Ultomiris is supplied as a concentrated solution in single-dose vials. This form is administered by a healthcare professional as an infusion into a vein (intravenous) after being diluted.

Subcutaneous Injection

Ultomiris is also available as a solution in a single-dose prefilled cartridge. This form is administered as an injection under the skin (subcutaneous) using a wearable on-body injector.

Question 10

What is the FDA approval status of Ultomiris?

Accepted Answer

FDA Approval and Indications

Ultomiris was first approved by the U.S. Food and Drug Administration (FDA) in December 2018. It is currently approved for the treatment of the following conditions:

Paroxysmal nocturnal hemoglobinuria (PNH): To treat adults and children one month of age and older.
Atypical hemolytic uremic syndrome (aHUS): To treat adults and children one month of age and older to inhibit complement-mediated thrombotic microangiopathy.
Generalized myasthenia gravis (gMG): To treat adults who are anti-acetylcholine receptor (AChR) antibody-positive.
Neuromyelitis optica spectrum disorder (NMOSD): To treat adults who are anti-aquaporin-4 (AQP4) antibody-positive.

Boxed Warning

Ultomiris carries a boxed warning regarding the risk of serious and life-threatening meningococcal infections. These infections can become fatal if they are not recognized and treated early. Because the medication interferes with the body's immune response, it increases susceptibility to specific types of bacteria.

REMS Program

Due to the risk of meningococcal infections, Ultomiris is only available through a restricted program called the Ultomiris REMS (Risk Evaluation and Mitigation Strategy). Requirements of this program include:

Healthcare providers who prescribe the medication must be specially certified and enrolled in the program.
Patients must be vaccinated against meningococcal infection at least two weeks before receiving their first dose, unless the treatment is urgent and cannot be delayed.
Patients must be monitored for early signs of infection and receive a Patient Safety Card that they must carry at all times during treatment.

Question 11

What should I know about Ultomiris and cost?

Accepted Answer

Factors Influencing Cost

The total cost of treatment with Ultomiris depends on several variables, including the patient's weight, the specific condition being treated, and the frequency of the maintenance doses. Because it is a specialty medication administered by healthcare professionals, costs also include the fees associated with the infusion site, such as a hospital or specialized clinic.

Insurance Coverage

Ultomiris is typically covered by most insurance plans, including Medicare and private insurance. However, the level of coverage and the resulting out-of-pocket expenses can vary. It is often processed under medical insurance benefits rather than a standard prescription drug plan.

Financial Support Options

Financial assistance may be available for patients who meet certain eligibility criteria. These options often include:

Co-pay Cards: Programs designed for patients with commercial insurance to help lower out-of-pocket costs.
Patient Assistance Programs: Support for individuals who are uninsured or underinsured, potentially providing the medication at a reduced cost or no cost.

Patients should consult with their insurance provider and healthcare team to obtain a precise estimate of their treatment costs and to explore available support programs.

Ultomiris

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Ultomiris

Hospitals.net Disclosure